Table 3.
VDRE stimulation and anti-inflammatory activities of 20S(OH)D3 analogs and their 1α-OH derivatives.
| Compound | VDRE stimulation (EC50 ± SD, nM) | IFNγ (ratio ± SD) | ||
|---|---|---|---|---|
| Caco-2 | HaCaT | Jurkat | ||
| 4 | 580.2 ± 19.2 | 460.4 ± 36.5 | 439.3 ± 25.7 | 0.832 ± 0.023* |
| 13 | NS | NS | NS | 0.824 ± 0.031** |
| 23 | NS | NS | NS | 0.698 ± 0.031*** |
| 33 | NS | NS | NS | 0.628 ± 0.014*** |
| 5 | 181.6 ± 6.1 | 197.8 ± 8.1 | 237.4 ± 5.5 | 0.381 ± 0.017*** |
| 14 | 188.0 ± 1.9 | 226.5 ± 3.5 | 248.4 ± 5.0 | 0.628 ± 0.008*** |
| 24 | 235.7 ± 4.1 | 254.1 ± 7.9 | 305.0 ± 4.5 | 0.560 ± 0.010*** |
| 20S(OH)D3 | NS | NS | NS | 0.517 ± 0.046*** |
| 1,25(OH)2D3 | 465.3 ± 20.9 | 305.2 ± 12.4 | 31.8 ± 4.5 | 0.397 ± 0.049*** |
| 22-Oxa | 42.5 ± 1.6 | 40.1 ± 1.5 | 2.9 ± 0.3 | 0.487 ± 0.017*** |
| Control | NA | NA | NA | 1.000 ± 0.015 |
SD: standard deviation, NS: no significance, NA: not applicable. *p < 0.05, **p < 0.01 and ***p < 0.001 compared with the control.